Polymorphisms of haemostasis genes as risk factors for preterm delivery

Summary

Clinical trials evaluating the potential benefit of anticoagulant treatment in pregnant women with inherited thrombophilia are based on the observation that a genetic predisposition to thrombosis is associated with frequent abortions and preterm birth. It was the aim of our study to delineate the impact of genetic polymorphisms with prothrombotic and antithrombotic effects on the occurrence of preterm birth in a large cohort of very-low-birth-weight (VLBW)-infants and their mothers. We examined the factor V Leiden and the prothrombin G20210A mutation, the factor VII 121del/ins and the factor XIII Val34Leu polymorphism in preterm very-low-birth-weight (VLBW, n=593) and term-born-infants (n=278) and their mothers (n=785).The primary outcome was preterm vs. term birth. From all polymorphisms tested, the maternal factor VII-121del/ins polymorphism (26.2 vs. 17.6 %; p=0.009) and the infant’s factor VII-121del/ins polymorphism (29.0 vs. 20.0 %; p=0.009) were more frequent in singletonVLBW and their mothers compared to term infants and their mothers. Furthermore, the frequency of the factor XIII-Val34Leu polymorphism was significantly lower in singleton VLBW than in term infant controls (5.1 vs. 9.6%, p=0.025). In a multivariate regression analysis, previous preterm delivery (OR=3.8, 95% CI: 1.7–8.4), the maternal carrier status of the factor-VII-121del/ins polymorphism (OR=1.7, 95% CI: 1.12–2.5, p=0.007) and the lower frequency of infant’s factor-XIII-Val34Leu polymorphism (OR=0.53; 95% CI: 0.29–0.96; p=0.038) were found to be independently associated with preterm delivery. InVLBW mothers with pathological CTG as cause of preterm delivery, the frequency of factor V Leiden mutation was significantly increased compared to VLBW mothers without pathological CTG (14.1 vs. 6.1%, p=0.01).The investigated haemostasis gene polymorphisms have a much lower impact on subsequent preterm delivery than known risk factors such as previous preterm birth. The reported association of the factor-VII-121del/ins polymorphism on preterm delivery and its clinical relevance needs to be further elucidated.

Keywords

Preterm delivery - coagulation system - factor VII/ factor XIII

• References

• 1 Goldenberg R, Rouse D. Medical progress: prevention of premature birth. N Engl J Med 1998; 339: 313-20.
• 2 Nelson DB, Ness RB, Grisso JA. et al. Influence of hemostatic factors on spontaneous abortion. Am J Perinatol 2001; 18: 195-201.
• 3 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
• 4 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and foetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
• 5 Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999; 353: 1411-2.
• 6 Kupferminc MJ, Fait G, Many A. et al. Low-molecular- weight heparin for the prevention ob obstretic complications in women with thrombophilias. Hypertens Pregnancy 2001; 20: 35-44.
• 7 Grandone E, Margaglione M. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. Thromb Haemost 2004; 2: 1187-8.
• 8 Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – Yes. J Thromb Haemost 2003; 1: 2070.
• 9 Gris J-C, Mercier E, Quéré I. et al. Low-molecularweight heparin vesus low-dose aspirin in women with one foetal loss and a constitutional thromboühilic disorder. Blood 2004; 103: 3695-9.
• 10 Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications − No. J Thromb Haemost 2003; 1: 2073.
• 11 Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database Syst Rev 2003; CD003580.
• 12 Li D-K, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs durino pregnancy and risk of miscarriage: population based cohort study. Br Med J 2003; 327: 1-5.
• 13 Nielsen GL, Sørensen HAT, Larsen H. et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J 2001; 322: 266-70.
• 14 Nielsen GL, Vinther Skriver M, Pedersen L, Sørensen HAT. Danish group reanalyses miscarriage in NSAID user. Br Med J 2004; 328: 109 [Letter].
• 15 Wells PS, Rodger MA. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications − No. J Thromb Haemost 2004; 2: 1188.
• 16 Nelson DB, Ness RB, Grisso JA. et al. Sex hormones, hemostasis, and early pregnancy loss. Arch Gynecol Obstet 2002; 267: 7-10.
• 17 Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Haemost 2003; 29: 171-4.
• 18 DeMaat MPM, Green F, de Knijff P. et al. Factor VII polymorphisms in populations with different risks of cardiovascular disease 1997; 17: 1918-23.
• 19 Humphries S, Temple A, Lane A. et al. Low plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (-323) insertion than the glutamine 353 variant. Thromb Haemost 1996; 75: 567-72.
• 20 Kudaravalli R, Tidd T, Pinotti M. et al. Polymorphic changes in the 5´flanking region of factor VII have a combined effect on promotor strength. Thromb Haemost 2002; 88: 763-7.
• 21 Ariens RA, Lai TS, Weisel JW. et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-54.
• 22 Kohler HP, Stickland MH, Ossei-Gerning N. et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
• 23 Catto AJ, Kohler HP, Coore J. et al. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
• 24 Elbaz A, Pirier O, Canaple S. et al. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
• 25 Franco RF, Reitsma PH, Lourenco D. et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81: 676-9.
• 26 Gopel W, Kattner E, Seidenberg J. et al. The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g. J Pediatr 2002; 140: 688-92.
• 27 Ridker PM, Hennekens CH, Lindpainter K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 13: 880-1 881 ff.
• 28 Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost 1997; 78: 1157-8.
• 29 Van Hylckama Vlieg A, Komanasin N, Ariens RA. et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119: 169-75.
• 30 Corral J, Iniesta JA, Gonzalez-Conejero R. et al. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 2001; 97: 2979-82.
• 31 Walker ID. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications No. Thromb Haemost 2004; 2: 1185.
• 32 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Haemost 2003; 29: 125-30.
• 33 Dizon-Townson DS, Meline L, Nelson LM. et al. foetal carriers of the factor-V-Leiden mutation are prone to miscarriae and placental infarction. J Obstet Gynecol 1997; 177: 402-5.
• 34 Kupferminc MJ, Eldor A. Inherited thrombophilia and gestational vascular complications. Semin Thromb Haemost 2003; 29: 185-94.
• 35 Mariani G, Herrmann H, Schulman S. et al. Thrombosis in inherited factor VII deficiency. Thromb Haemost 2003; 1: 2153-8.
• 36 Craven CM, Chedwick LR, Ward K. Placental basal plate formation is associated with fibrin deposition in decidual veins at sites of trophoblast cell invasion. Am J Obstet Gynecol 2002; 186: 291-6.
• 37 Anwar R, Gallivan L, Edmonds SD. et al. Genotype/ phenotype correlations for coagulation factor XIII : specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905.